论文信息 - O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC - 字舞流文

O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

G. Giaccone | N. Reinmuth | R. Herbst | J. Jassem | C. Barrios | M. Mccleland | D. Spigel | A. Vergnenègre | H. Kuriki | K. Komatsubara | F. Marinis | Sarayut Lucien Geater | M. Ozguroglu | M. Morise | Z. Andrić | S. Mocci | I. Enquist | X. Wen | Y. Deng | E. Font